# TD Cowen

Type: Company

Source: Healthcare Intelligence Brief — https://gethealthbrief.com/entity/td-cowen
Canonical HTML page: https://gethealthbrief.com/entity/td-cowen

## Timeline

- **2026-03-22**: Market Outperformance — Grail shares end the week as a top performer in the healthcare sector, recouping major losses.
- **2026-03-18**: TD Cowen Upgrade — TD Cowen upgrades Grail to 'Buy,' arguing the market overreacted to the leadership change.
- **2026-03-13**: CEO Transition & Setback — CEO Bob Ragusa retires following reports of a clinical trial setback, causing a sharp drop in GRAL shares.

## Recent coverage (3 stories)

### Amylyx Cuts Low Blood Sugar Episodes 55% After Bariatric Surgery
2026-08-18 22:32:01 · Sentiment: Positive · Impact: 6/10 · Sources: 2

A late-stage trial found Amylyx's once-daily injection avexitide reduced hypoglycemic episodes by 55% in people with post-bariatric hypoglycemia, a condition with no approved treatments. The drug was well tolerated, and the company plans a U.S. filing by end of 2026. For health systems and clinicians, the result signals a potential first-ever standard therapy that could change post-bariatric care.
Full story: https://gethealthbrief.com/story/amylyx-avexitide-post-bariatric-hypoglycemia-health

### Grail Shares Surge as Analysts Call Recent Selloff a "Buying Opportunity"
2026-03-22 12:10:34 · Sentiment: Positive · Impact: 6/10 · Sources: 2

Grail (GRAL) stock staged a major recovery this week, outperforming the broader market after a pivotal upgrade from TD Cowen. The rally marks a significant shift in investor sentiment following a volatile period triggered by a CEO transition and clinical trial concerns.
Full story: https://gethealthbrief.com/story/grail-stock-recovery-analysis-march-2026

### Analysts Slash Veeva Systems Price Targets Amid Vault CRM Migration Risks
2026-03-08 13:42:50 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Veeva Systems is facing a wave of price target reductions from major analysts, including TD Cowen and Canaccord Genuity, reflecting caution over its platform transition. While management maintains a $6 billion revenue target for 2030, recent disclosures of competitive losses have tempered market enthusiasm.
Full story: https://gethealthbrief.com/story/veeva-systems-price-target-cuts-analysis

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://gethealthbrief.com/guides/methodology for the full editorial methodology.